# Lin Wu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lin-wu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,151 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 61 |
| i10-index | 185 |
| Last Known Institution | Central South University |
| OpenAlex ID | https://openalex.org/A5086270619 |
| ORCID iD | 0000-0001-7078-7767 |
| Works | 458 |

## Researcher papers

Showing 12 of 20.

- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program](https://scholariq.org/papers/myc-bcl2-protein-coexpression-contributes-to-the-inferior-survival-of-activated/)
- [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-anlotinib-as-a-third-line-or-further-treatment-on-overall-survival-of/)
- [Aristolochic acid and the etiology of endemic (Balkan) nephropathy](https://scholariq.org/papers/aristolochic-acid-and-the-etiology-of-endemic-balkan-nephropathy/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii/)
- [Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial](https://scholariq.org/papers/gene-mutations-and-treatment-outcome-in-chronic-lymphocytic-leukemia-results/)
- [Perioperative Nivolumab in Resectable Lung Cancer](https://scholariq.org/papers/perioperative-nivolumab-in-resectable-lung-cancer/)
- [Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy](https://scholariq.org/papers/detection-and-dynamic-changes-of-i-egfr-i-mutations-from-circulating-tumor-dna/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/)
- [Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer](https://scholariq.org/papers/perioperative-toripalimab-plus-chemotherapy-for-patients-with-resectable-non/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Central South University](https://scholariq.org/institutions/central-south-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.